Highlights Lytix Biopharma

Equities

LYTIX

NO0010405780

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-31 am EDT			5-day change	1st Jan Change
6.4 ^NOK	+1.59%		+6.67%	+31.69%

May. 30	Transcript : Lytix Biopharma AS, Q1 2024 Earnings Call, May 30, 2024
Apr. 25	Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity	Apr. 25	CI
Lytix Biopharma to Raise Up to NOK55 Million via Share Offering	Apr. 10	MT
Lytix Biopharma AS Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Lytix Biopharma AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Lytix Biopharma as Announces Encouraging Results from ATLAS-It-04 Study Published in Oncoimmunology	Dec. 11	CI
Lytix Biopharma AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Lytix Biopharma Secures NOK14.3 Million Research Grant for Skin Cancer Treatment	23-10-17	MT
Lytix Biopharma AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31	CI
Lytix Biopharma AS Completes Recruitment of 20 Patients in the ATLAS-IT-05 Trial	23-08-28	CI
Lytix Biopharma's Licensing Partner Verrica Pharmaceuticals Inc. Reports Interim Phase 2 Data with LTX-315	23-08-11	CI
Lytix Biopharma AS Announces Presentation of Interim Data from ATLAS-IT-05 Study at ESMO 2023	23-07-19	CI
Lytix Biopharma AS Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Lytix Biopharma AS Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16	CI
Lytix Biopharma AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-16	CI
Lytix Biopharma AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-17	CI
Lytix Biopharma AS Announces Expansion of the ATLAS-IT-05 Study to Europe	22-11-14	CI
Lytix Biopharma Announces Site Activation for the ATLAS-IT-05 Study in Three European Countries	22-11-13	CI
Lytix Biopharma AS Presents Compelling Data in Collaboration with Research Groups At National Cancer Institute and Weill Cornell Medicine, USA	22-11-10	CI
Lytix Biopharma Jumps 10% on Approval for Advanced Melanoma Treatment Study in Three European Countries	22-09-07	MT
Lytix Biopharma AS Announces Approval to Expand the ATLAS-IT-05 Study to Europe	22-09-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lytix Biopharma

Equities

LYTIX

NO0010405780

Highlights

Filters